Literature DB >> 7477351

Partial activation of CD8+ T cells by a self-derived peptide.

W Cao1, S S Tykodi, M T Esser, V L Braciale, T J Braciale.   

Abstract

T cells are normally activated when the peptide for which they are specific is presented to them in the context of the appropriate major histocompatibility complex (MHC) (class I and Class II for CD8+ and CD4+ T cells, respectively). An increasing body of evidence indicates that structural homologues of the immunogenic peptide can partially activate or antagonize CD4+ T cells. CD8+ T cells may also be partially antagonized by such peptides, and self-derived peptides of this type may play a role in CD8+ T cell selection in the thymus. Activated CD8+ T cells lyse their targets by perforin-dependent granule exocytosis and by inducing apoptosis mediated by CD95 (also known as Fas or APO1) with its ligand (CD95L). Here we show that a clone of Kd-restricted CD8+ T cells specific for influenza haemagglutinin, which can also be activated in a crossreactive manner by a peptide derived from a myeloma tumour immunoglobulin heavy-chain variable region (IgVH) to kill by both routes, kills only by the CD95-CD95L pathway when stimulated by the corresponding germline IgVH peptide. As this germline IgVH peptide differs from the tumour peptide only at a single position buried in the MHC-binding groove, this indicates that CD95-CD95L-mediated killing can be triggered independently of the perforin-mediated pathway, and can be selectively affected by changes in MHC conformation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477351     DOI: 10.1038/378295a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  21 in total

Review 1.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 2.  Major histocompatibility complex molecules on parenchymal cells of the target organ protect against autoimmune disease.

Authors:  Hui Shao; Henry J Kaplan; Deming Sun
Journal:  Chem Immunol Allergy       Date:  2007

Review 3.  The role of Fas-FasL in CD8+ T-cell-mediated insulin-dependent diabetes mellitus (IDDM).

Authors:  H T Kreuwel; L A Sherman
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

4.  IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes.

Authors:  A Amrani; J Verdaguer; S Thiessen; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

5.  Fas-dependent CD4+ cytotoxic T-cell-mediated pathogenesis during virus infection.

Authors:  A J Zajac; D G Quinn; P L Cohen; J A Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

6.  Regulation of IFN-gamma signaling is essential for the cytotoxic activity of CD8(+) T cells.

Authors:  G Z Tau; S N Cowan; J Weisburg; N S Braunstein; P B Rothman
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

7.  Antigen-specific inhibition of CD4+ T-cell responses to beta-lactoglobulin by its single amino acid-substituted mutant form through T-cell receptor antagonism.

Authors:  M Totsuka; S Furukawa; E Sato; A Ametani; S Kaminogawa
Journal:  Cytotechnology       Date:  1997       Impact factor: 2.058

8.  Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice.

Authors:  A Amrani; J Verdaguer; B Anderson; T Utsugi; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

9.  Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease.

Authors:  R I Enelow; A Z Mohammed; M H Stoler; A N Liu; J S Young; Y H Lou; T J Braciale
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

10.  Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity.

Authors:  Anil Shanker; Alan D Brooks; Kristen M Jacobsen; John W Wine; Robert H Wiltrout; Hideo Yagita; Thomas J Sayers
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.